Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
Clearmind Medicine Inc. (NASDAQ:CMND) filed a patent application for its combination therapy involving Ibogaine and N-Acylethanolamines.
What Happened: The therapy was developed in collaboration with SciSparc Ltd. (NASDAQ:SPRC). It combines the psychedelic compound Ibogaine with Palmitoylethanolamide (PEA), which is a member of the N-Acylethanolamines family. It aims to improve the safety and efficacy of Ibogaine-based treatments.
Ibogaine, derived from the African shrub Tabernanthe iboga, has already shown potential in addressing opioid, cocaine, and other substance use disorders.
See Also: GH Research: This European Biotech Company Reports Full Year …